Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Retrospective and Prospective Longitudinal Observational Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Descripción general del estudio
Estado
Descripción detallada
Invasive fungal disease refers to a severe infection caused by fungi invading human tissues, blood or body fluids, mainly affecting people with weakened immune systems. Under the background of HSCT, due to the transplantation recipients undergoing high-dose chemotherapy pretreatment, graft-versus-host disease (GVHD), and the use of immunosuppressants, the immune function of the body is severely impaired, and the risk of IFD occurrence significantly increases. The clinical manifestations of IFD after HSCT are diverse, which can involve multiple organs and systems such as the lungs, blood, central nervous system, and skin. It is difficult to diagnose, challenging to treat, and has a poor prognosis, seriously affecting the long-term survival and quality of life of transplant patients.
In recent years, the epidemiological characteristics of IFD after HSCT have undergone significant changes. According to the CAESAR 2.0 study, among 2015 Chinese patients who received allo-HSCT, the cumulative one-year incidence of IFD (proven + probable) was 6.3%. It is worth noting that compared with the CAESAR study ten years ago, the pathogen spectrum has undergone a significant transformation, which is closely related to the evolution of antifungal prevention strategies - ten years ago, fluconazole was mainly used for prevention, while currently about three quarters of patients use antifungal active drugs such as voliconazole or posaconazole. Although this shift in preventive strategies has reduced the occurrence of aspergillosis, it may increase the risk of infection from drug-resistant pathogens such as Mucor.
IFD after HSCT remains a major clinical challenge affecting the prognosis of patients. The current research has the following deficiencies: (1) There is still a lack of multi-center, large-sample prospective cohort studies in China; (2) The dynamic changes in the pathogen spectrum and clinical characteristics of IFD require continuous monitoring. (3) The diagnosis and treatment strategies and prognostic factors of different types of IFD need in-depth research. Based on the above background, this study intends to establish a longitudinal observational cohort that combines retrospective and prospective approaches to systematically evaluate the epidemiological characteristics, treatment strategies, and short-term and long-term outcomes of IFD patients after HSCT.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jin Wu, MD
- Número de teléfono: 086-01088326002
- Correo electrónico: wujin1996@126.com
Copia de seguridad de contactos de estudio
- Nombre: Fanhao Nie
- Número de teléfono: 086-18887323790
- Correo electrónico: Niefh2003@163.com
Ubicaciones de estudio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100044
- Reclutamiento
- Peking University People's Hospital
-
Contacto:
- Xiaohui Zhang, MD
- Número de teléfono: 01088326666
- Correo electrónico: wujin1996@126.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Study population:
Patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers since January 1, 2014.
Outcome Assessment:
Patients were followed up for the development of invasive fungal disease (IFD) after transplantation.
Descripción
Inclusion Criteria:
Since January 1, 2014, patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers.
Exclusion Criteria:
- For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;
- Patients deemed unsuitable for the study by the researchers.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Cohorte retrospectivo
Los pacientes cuya primera visita a nuestra institución y la terminación del seguimiento ocurrieron antes de la apertura de este estudio contribuirán a la cohorte retrospectiva.
|
|
Cohorte prospectivo
Los pacientes cuya primera visita a nuestra institución ocurre después de la apertura de este estudio contribuirá a la cohorte prospectiva.
|
|
Cohorte retrospectiva/prospectiva
Los pacientes cuya primera visita a nuestra institución ocurrió antes de la apertura de este estudio y cuyo seguimiento terminará después de la apertura de este estudio contribuirá a la cohorte ambispectiva.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival after allo-HSCT, measured as time from transplantation to death from any cause
Periodo de tiempo: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first
|
Overall survival is defined as the time from the date of allogeneic hematopoietic stem cell transplantation to death from any cause.
Participants without documented death will be censored at the date of last contact or at 5 years after transplantation, whichever occurs first.
Overall survival probabilities at 1, 3, and 5 years after transplantation will be estimated using the Kaplan-Meier method.
|
From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants with invasive fungal disease who have overall response at 1 year
Periodo de tiempo: 1 year after diagnosis of invasive fungal disease
|
Overall response of invasive fungal disease is defined as complete response or partial response at 1 year after diagnosis of invasive fungal disease.
Response will be assessed according to the Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria for treatment response in invasive fungal diseases.
Participants who die before the 1-year assessment or do not meet complete or partial response criteria will be classified as not having overall response.
The outcome will be summarized as the number and percentage of participants with complete or partial response.
|
1 year after diagnosis of invasive fungal disease
|
|
Cumulative incidence of proven or probable invasive fungal disease within 1 year after allo-HSCT
Periodo de tiempo: From date of allo-HSCT to first diagnosis of invasive fungal disease, death, last contact, or 1 year after allo-HSCT, whichever occurs first
|
Invasive fungal disease is defined as the first episode of proven or probable invasive fungal disease after allo-HSCT according to protocol-defined diagnostic criteria based on EORTC/MSGERC definitions.
Death before invasive fungal disease will be treated as a competing event.
Participants who do not develop invasive fungal disease and do not die will be censored at the date of last contact or at 1 year after allo-HSCT, whichever occurs first.
The cumulative incidence function will be used to estimate the incidence of invasive fungal disease.
|
From date of allo-HSCT to first diagnosis of invasive fungal disease, death, last contact, or 1 year after allo-HSCT, whichever occurs first
|
|
Number and percentage of participants with post-transplant complications within 5 years after allo-HSCT
Periodo de tiempo: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first
|
Post-transplant complications include acute graft-versus-host disease, chronic graft-versus-host disease, cytomegalovirus infection or reactivation, Epstein-Barr virus infection or reactivation, bacterial bloodstream infection, organ dysfunction, relapse of the underlying hematologic disease, graft failure, intensive care unit admission.
The outcome will be summarized as the number and percentage of participants with at least one post-transplant complication and by complication category.
|
From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first
|
|
Number and percentage of participants with treatment-related adverse events as assessed by CTCAE v5.0
Periodo de tiempo: From initiation of systemic antifungal therapy to 30 days after the last dose, death, or last contact, whichever occurs first
|
Treatment-related adverse events are adverse events considered related to systemic antifungal therapy.
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
The outcome will be summarized as the number and percentage of participants with at least one treatment-related adverse event.
Grade 3 or higher adverse events and serious adverse events will be summarized separately.
|
From initiation of systemic antifungal therapy to 30 days after the last dose, death, or last contact, whichever occurs first
|
|
Total length of hospital stay within 5 years after allo-HSCT, measured in inpatient days
Periodo de tiempo: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first.
|
Total length of hospital stay is defined as the cumulative number of inpatient days recorded for each participant after allogeneic hematopoietic stem cell transplantation and before death, last contact, or 5 years after transplantation, whichever occurs first.
The outcome will be summarized as inpatient days per participant using descriptive statistics.
|
From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Xiao-Hui Zhang, MD, Peking University Institute of Hematology, Peking University People's Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HSCT-IFD2026
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .